Complement, Coagulation & FcRn

Cat. No.

AT1539

CAS No.

2250440-41-4

Vilobelimab

Synonyms: CaCP-29; IFX-1

Vilobelimab (CaCP-29, IFX-1) is a monoclonal antibody specifically targeting C5a, a potent pro-inflammatory peptide derived from the complement system. By binding to C5a, Vilobelimab effectively inhibits its interaction with the C5a receptor, thereby attenuating neutrophil activation and chemotaxis. This inhibition plays a crucial role in reducing inflammatory signaling pathways associated with severe clinical conditions such as organ dysfunction. Vilobelimab is highly relevant for research in pathological states where the complement cascade contributes to disease progression, including sepsis and COVID-19.

Cat. No.

AT1541

CAS No.

2857858-84-3

Armocibart

Armocibart is a human monoclonal antibody of the IgG4κ subtype designed to target Tissue Factor Pathway Inhibitor (TFPI). For experimental controls, it is recommended to use Human IgG4 (S228P) kappa as an isotype control.

Cat. No.

B18277

CAS No.

2901809-66-1

Inclocibart

Synonyms: BAY-3018250

Inclocibart is a humanized IgG4 lambda1 antibody specifically targeting SERPINF2. This antibody is designed for use in various research applications, including studies on extracellular matrix regulation and tissue remodeling. Its effectiveness in modulating SERPINF2 activity makes it a valuable tool for investigating related pathological conditions.

Cat. No.

B18401

CAS No.

3036400-21-9

Latarcibart

Synonyms: VGA-039

Latarcibart is a humanized IgG4κ antibody that specifically targets Protein S (PROS1). It is designed for applications in the study of anticoagulation, tumor biology, and immune response, where Protein S plays a critical role in coagulation pathways and immune regulation. This antibody facilitates research into the mechanisms of thrombosis and cellular immunity, enabling deeper insights into related diseases.